Bio-Hep-B vaccine

12.09.2010

You are here

Prof. Yosef Shaul
 
Prof. Yosef Shaul studies the processes by which viruses interact with cells. In particular, he has been able to define the molecular mechanisms employed by the hepatitis B virus.
 

Application

 
Bio-Hep-B, a vaccine for hepatitis B based on Prof. Shaul's research, is produced by Biotechnology General and marketed in Israel; registrations in other countries are under way. Hepatitis B affects an estimated 150 million people in Africa and Asia.
 

Share